At ChinaBio Partnering Forum 2010 jointly organized by Suzhou BioBay, ChinaBio, and EBD Group at Cold Spring Harbor Asia Conference Center, Dr. Richard Wang, Director of Strategic Alliance and Collaboration at AstraZeneca, one of the world's leading biopharmaceutical companies based in UK, said cooperation was a general trend in the global bio-med community.

As an experienced expert in the field, Dr. Wang has an in-depth understanding of the industrial current status and future trend. He pointed out that, after years of development, what left for the researchers to find solutions to on the new drug list were difficult ones featuring high R&D risk, which makes cooperation the most effective and the most efficient way to realize new progresses in the sector.

June 23, 2010